Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
blood cancer
Biotech
Merck mulls PV program’s future while Takeda takes victory lap
Merck revealed the first look at data from a phase 2 trial of bomedemstat, while Takeda shared updated results from rusfertide's phase 3 study.
Darren Incorvaia
Dec 8, 2025 4:30pm
Nurix trims staff as trial for lead BTK degrader kicks off
Nov 21, 2025 5:05am
Genmab sheds another clinical ADC from $1.8B ProfoundBio buy
Nov 17, 2025 2:17pm
Roche's Flatiron Health debuts 6 new blood cancer data sets
Oct 29, 2025 9:00am
Ignota buys Kronos' pipeline to rescue shelved programs
Oct 6, 2025 5:45am
Gilead's Kite erodes $2.3B Shoreline cell therapy deal
Sep 3, 2025 3:18pm
